Pipeline

ABL503

HomePipelineABL503

  • Pipeline
    ABL503
  • Program Target
    PD-L1 x 4-1BB
  • Disease Indication
    Solid Tumor
  • Development Stage
    Early Development
Summary
ABL503 is a bispecific antibody combining PD-L1 checkpoint pathway with 4-1BB agonistic activity to overcome the current limitation of PD-(L)1 therapy and 4-1BB related toxicity. ABL503 is full length anti-PD-L1 mAb (Fc-silenced human IgG1) fused with scFv of anti-4-1BB engaging mAb. ABL503 possesses unique properties that 4-1BB activation signal is only induced in the presence of PD-L1 expressing tumors. ABL503 shows superior anti-tumor activity in an animal model system than PD-L1 alone, 4-1BB alone or combination of both with immunological memory resistant to rechallenge with same tumors.

Structure and Mechanism of Action

Structure and Mechanism of Action
좌우스크롤 Structure and Mechanism of Action

PD-L1 Dependent 4-1BB Activation

PD-L1 Dependent 4-1BB Activation
PD-L1 Dependent 4-1BB Activation

Superior Anti-Tumor Effect with Immunological Memory

Superior Anti-Tumor Effect with Immunological Memory
Superior Anti-Tumor Effect with Immunological Memory